Terapevticheskii Arkhiv最新文献

{"title":"[Long-term goflkicept therapy for patients with idiopathic recurrent pericarditis: results of the interim analysis of an ongoing open-label extension study].","authors":"V Y Myachikova, A L Maslyanskiy, O M Moiseeva, M L Schedrova, A N Egorova, Е G Ponomar, M Y Samsonov","doi":"10.26442/00403660.2024.09.202984","DOIUrl":"10.26442/00403660.2024.09.202984","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the long-term safety and efficacy of goflkicept treatment in patients with idiopathic recurrent pericarditis (IRP).</p><p><strong>Materials and methods: </strong>This report presents the interim analysis of an ongoing open-label extension (OLE) clinical trial of goflkicept in patients with IRP (NCT05673902), as a continuation of the core study (NCT04692766). The study assessed the frequency of pericarditis recurrence, time to recurrence after 12 and 60 weeks of goflkicept therapy, changes in C-reactive protein level, chest pain intensity, pericardial effusion size, and adverse events (AEs).</p><p><strong>Results: </strong>All patients remained in clinical-laboratory remission during the 60 weeks of goflkicept treatment. The recurrence frequency was 31.3% (5/16) after 60 weeks and 90% (9/10) after 12 weeks of goflkicept treatment (p</i><</i>0.001). A total of 64 AEs were reported in 16 patients (94.1%), mostly of mild to moderate severity. The most common AEs were infections, occurring in 11 patients (64.7%). Nine serious adverse events were reported in 5 patients, none of which were considered drug-related. There were no deaths.</p><p><strong>Conclusion: </strong>Long-term goflkicept therapy resulted in a significant reduction in the risk of recurrence and prolonged remission without an increase in adverse events.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 9","pages":"892-900"},"PeriodicalIF":0.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure with reduced left ventricular ejection fraction in various subgroups of standard therapy in the Russian Federation].","authors":"S V Nedogoda, M V Zhuravleva, S N Tereshchenko, A S Salasyuk, I V Zhirov, I N Barykina, V O Lutova, E A Popova","doi":"10.26442/00403660.2024.08.202915","DOIUrl":"https://doi.org/10.26442/00403660.2024.08.202915","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the clinical and economic effectiveness of dapagliflozin in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (HFrEF) in the Russian Federation in various subgroups of standard therapy for CHF.</p><p><strong>Materials and methods: </strong>A clinical and economic analysis of the use of the drug dapagliflozin in addition to standard therapy was carried out in comparison with standard therapy in various subgroups of standard therapy for HFrEF using a modeling method. Cost calculations were carried out in a mathematical model adapted to the healthcare conditions of the Russian Federation by using Russian cost indicators and characteristics of the patient population.</p><p><strong>Results: </strong>The present study demonstrates that the addition of dapagliflozin is beneficial in terms of clinical and cost-effectiveness, regardless of the initial regimen (angiotensin receptor-neprilysin inhibitors [ARNI] or angiotensin-converting enzyme inhibitors [ACEi]/angiotensin II receptor blockers [ARB]) of standard drug therapy for HFrEF and in all cases leads to an increase in life expectancy, a decrease in the number of hospitalizations and emergency visits due to CHF, as well as cardiovascular mortality. The obtained values of added value per additional year of life in all cases are significantly lower than the willingness-to-pay threshold, which indicates the clinical and economic effectiveness of the strategy of prescribing dapagliflozin as part of standard therapy for patients with HFrEF. In the case of adding dapagliflozin the values of the additional cost of an added year of life in the 3 considered standard therapy options (ARNI or ACEi/ARB, only ACEi/ARB and only ARNI) were 291,256, 279,571 and 338,374 rubles respectively. Thus, the scenario of using dapagliflozin with standard therapy, which included only ACEi/ARB, is characterized by the lowest additional cost and has the best clinical and economic characteristics. At the same time the scenario of use with standard therapy, which included only ARNI, is characterized by the highest value of the additional value of the added year of life.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"771-779"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Detection of anticoagulant medication errors by triggers].","authors":"V A Otdelenov, E B Kleymenova, M D Nigmatkulova, S A Payushchik, O D Dukhanina, L P Yashina, D A Sychev","doi":"10.26442/00403660.2024.08.202817","DOIUrl":"https://doi.org/10.26442/00403660.2024.08.202817","url":null,"abstract":"<p><strong>Background: </strong>Medication errors can cause preventable adverse events. For example, inappropriate use of anticoagulants (AC) can result in bleeding and thromboembolic complications. Detection and analysis of AC medication errors allow to reveal deficiencies in the safety systems in healthcare organizations.</p><p><strong>Aim: </strong>The study was aimed to develop a method of systematic detection of anticoagulant medication errors for consequent audit, analysis and development of medication safety improvement measures.</p><p><strong>Materials and methods: </strong>The study was conducted in the multidisciplinary hospital and included 4924 patients admitted from January 2019 to December 2021 who received AC. Three laboratory triggers (international normalized ratio ≥4, serum creatinine ≥133 μmol/l, and glomerulofiltration rate <30 ml/min/1.73 m²) helped to reveal 4304 cases. Their matching with patient's data helped to develop combined triggers. Two clinical pharmacologists reviewed all cases identified by combined triggers for checking medication errors. The trigger was considered positive when anticoagulant medication error was detected in the history selected by combined trigger.</p><p><strong>Results: </strong>Of the 4924 patients 253 (5.3%) were selected by combined triggers. Combined trigger allowed to reduce the amount of medical health records audit by 97.3%. Medication errors were detected in 137 patients. Positive predictive value of selected combined triggers varied from 0 to 63.9%. Aggregated positive predictive value of all combined triggers amounted to 54.2%. AC medication errors were detected in 2.8% patients.</p><p><strong>Conclusion: </strong>Method of systematic detection of AC medication errors using combined triggers in all hospitalized patients receiving AC allowed to reveal typical medication errors for consequent analysis and elaboration of measures to reduce preventable patient harm in healthcare settings.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"744-750"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study].","authors":"A N Sasunova, A А Goncharov, K M Gapparova, V A Isakov","doi":"10.26442/00403660.2024.08.202810","DOIUrl":"https://doi.org/10.26442/00403660.2024.08.202810","url":null,"abstract":"<p><strong>Aim: </strong>To study the impact of type 2 diabetes mellitus (DM2) on the severity of liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).</p><p><strong>Materials and methods: </strong>To conduct a paired case-control study 2989 patients were examined at the Federal Research Center of Nutrition, Biotechnology and Food Safety. Pairs were matched by gender and age and distributed into groups: NAFLD + DM2+ (<i>n</i>=313), NAFLD + DM2- (n=313) and a control group of patients without NAFLD and without DM2 (<i>n</i>=313). The severity of liver steatosis was determined by measuring the controlled attenuation parameter. The severity of liver fibrosis was determined by measuring the liver stiffness measurement. Body composition of the patients was determined using bioimpedance measurements. Indicators of lipid and carbohydrate metabolism, and the serum activity of liver enzymes was determined by standard biochemical methods.</p><p><strong>Results: </strong>In NAFLD + DM2+ group compared to NAFLD + DM2- group, and in NAFLDM + DM2-compared to the control group, weight, BMI, waist and hip circumference, waist-to-hip ratio were higher, while in all. In NAFLD + DM2+ and NAFLD + DM2- groups the volume of fat mass directly correlated with the level of blood triglycerides (<i>r</i>=0.21), HbA₁_с (<i>r</i>=0.32) and fasting blood glucose (<i>r</i>=0.35), and inversely correlated with high-density lipoproteins (<i>r</i>=-0.19). In NAFLD + DM2+ group versus NAFLD + DM2- group severe steatosis (S3, 78% versus 59.4%; <i>p<</i>0.001) and severe fibrosis (F4, 8% vs 2.6%; <i>p<</i>0.001) was more common; 70% of patients in the NAFLD + DM2- group had no liver fibrosis according to elastography (F0), while in the NAFLD + DM2+ group only 43.2% of patients had no liver fibrosis (<i>p<</i>0.0001).</p><p><strong>Conclusion: </strong>When NAFLD is accompanied by DM2, there is an increase in total fat mass, the severity of steatosis and liver fibrosis, and an associated deterioration of lipid metabolism. More than half of these patients have various stages of liver fibrosis, which indicates the progressive nature of the disease.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"764-770"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy of rabeprazole for the treatment of gastroesophageal reflux disease in a 7-day non-interventional trial].","authors":"V V Tsukanov, E V Onuchina, A V Vasyutin, B B Dambaeva, J L Tonkikh, N V Pavlova","doi":"10.26442/00403660.2024.08.202895","DOIUrl":"10.26442/00403660.2024.08.202895","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy of seven-day treatment with rabeprazole (Razo^®) 20 mg once daily in patients with NERD and esophagitis based on monitoring the results of pH-impedancemetry of the stomach and esophagus and assessment of clinical symptoms.</p><p><strong>Materials and methods: </strong>Thirty patients with typical GERD manifestations were examined. The study included patients who underwent pH-impedancemetry, endoscopic examination, and were prescribed treatment with rabeprazole at a dose of 20 mg once a day. Clinical monitoring was performed during three visits: before treatment, after 3 days, and after 7 days of treatment. Control pH-impedancemetry was performed after 7 days of therapy. The third visit was the endpoint of the study.</p><p><strong>Results: </strong>After 7 days of treatment, the response rate for heartburn was 86.7% in the overall group of patients with GERD, 94.4% in those with NERD, and 75.0% in patients with esophagitis stage A and B. After 7 days of therapy with rabeprazole, we registered a significant decrease in the total number of refluxes (from 88 to 54; <i>p<</i>0.001), the number of acid refluxes (from 53 to 22; <i>p<</i>0.001), the DeMeester index (from 23.81 to 7.62; <i>p<</i>0.001), and AET (from 7.54 to 2.01; <i>p<</i>0.001) in the esophagus and an increase in the median daily pH (from 1.8 to 5.4; <i>p<</i>0.001) and the time with pH>4 in the stomach (from 2.57 hours and 10.7% up to 12.3 hours and 51.3%; <i>p<</i>0.001). 7-day therapy with rabeprazole was accompanied by a significant improvement in GERD patients in all parameters of quality of life. 100% of patients with GERD rated their satisfaction with therapy as \"good\" and \"very good\".</p><p><strong>Conclusion: </strong>As a result of 7-day therapy of patients with NERD and esophagitis with Razo^® at a dose of 20 mg per day, an excellent clinical response was obtained, confirmed by a marked optimization of pH-impedancemetry parameters.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"804-811"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Ferritin as a biomarker of aging: geroprotective peptides of standardized human placental hydrolysate. A review].","authors":"O A Gromova, I I Torshin, A G Chuchalin","doi":"10.26442/00403660.2024.08.202811","DOIUrl":"10.26442/00403660.2024.08.202811","url":null,"abstract":"<p><p>Ferritin, an iron transport protein, is an acute phase protein of inflammation and oxidative stress (OS), a biomarker of cytolysis and ferroptosis. Inflammation, OS and iron overload are characteristic processes of the pathophysiology of aging. Human placental hydrolysates (HPHs) are promising hepatoprotective agents for anti-aging therapy. The goal of the team of authors was to systematize data on ferritin as a marker of aging and to identify peptides that counteract the aging pathophysiology, including through the regulation of iron and ferritin metabolism, in the HPH Laennec (manufactured by Japan Bioproducts). The results of basic and clinical studies confirm the above relationships and indicate that blood ferritin levels characterize the chronological and biological aging of the human body.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"826-835"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[On the institutionalization of Russian pulmonology: the second and third stages of its history].","authors":"V I Borodulin, E N Banzelyuk, A V Topolyanskiy","doi":"10.26442/00403660.2024.08.202808","DOIUrl":"https://doi.org/10.26442/00403660.2024.08.202808","url":null,"abstract":"<p><p>For the first time, the authors conducted a historical analysis of primary sources and identified 3 stages in the history of Russian pulmonology, naming 8 of its founders. The content is disclosed in two articles (the first one was published in No. 3 of our journal for 2024). This article tells about the second (pulmonology as an independent scientific and educational discipline within the clinic of internal diseases) and the third (as a new medical specialty) stages of the history of Russian pulmonology in the XX century.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"852-855"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Possibilities of post-processing of multislice computed tomography results in non-invasive diagnosis of pancreatic fibrosis].","authors":"I E Khatkov, K A Lesko, E A Dubtsova, S G Khomeriki, N S Karnaukhov, L V Vinokurova, E I Shurygina, N V Makarenko, R E Izrailov, I V Savina, D A Salimgereeva, M A Kiriukova, D S Bordin","doi":"10.26442/00403660.2024.08.202831","DOIUrl":"https://doi.org/10.26442/00403660.2024.08.202831","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the possibilities of post-processing of multidetector computed tomography (CT) results in the non-invasive diagnosis of pancreatic fibrosis (PF).</p><p><strong>Materials and methods: </strong>The study included 165 patients aged 57.91±13.5 years who underwent preoperative CT during surgical treatment for chronic pancreatitis and pancreatic cancer from April 2022 to February 2024. The normalized contrast ratios of pancreatic tissue in the pancreatic (NCPP) and venous (NCVP) phases, as well as the contrast ratio (CR) were measured. Pathomorphological assessment of PF performed in tissues outside neoplasm or desmoplastic reaction by the Kloppel and Maillet scale.</p><p><strong>Results: </strong>The values of post-processing CT results were compared in groups with different degrees of PF. Mean CR values were significantly higher (<i>p=</i>0.001) in patients with severe PF (CR 1.16±0.65 HU) than in patients with mild PF (CR 0.78±0.31 HU). CR value significant increase (<i>p=</i>0.03) was found in patients with signs of inflammatory changes in the pancreas tissue (CR 1.14±0.6 HU) than in those without them (CR 0.81±0.3 HU). There were no significant differences between the values of NCPP and NCVP, and the degree of PF.</p><p><strong>Conclusion: </strong>The CR value increased in patients with severe degree of PF. There was a relationship between CR value increase and the radiological density of pancreatic tissue in non-contrast phase and presence of early signs of pancreatic inflammatory changes. Thus, there was a relationship between CT postprocessing results and morphological signs of PF, which can be used for pancreatic fibrosis non-invasive diagnosis and identification of additional signs of early chronic pancreatitis.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"780-789"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prevalence of gastroesophageal reflux disease in Russia: a meta-analysis of population-based studies].","authors":"D N Andreev, I V Maev, D S Bordin, S R Abdulkhakov, R I Shaburov, P S Sokolov","doi":"10.26442/00403660.2024.08.202807","DOIUrl":"10.26442/00403660.2024.08.202807","url":null,"abstract":"<p><strong>Aim: </strong>To systematize data on the prevalence of gastroesophageal reflux disease (GERD) in the adult population of Russia.</p><p><strong>Materials and methods: </strong>The search for studies was conducted in the electronic databases MEDLINE/PubMed, EMBASE, and RSCI (Russian Science Citation Index) from January 2000 to December 2022. The review included relevant publications in peer-reviewed periodicals in English or Russian, publications with data from cross-sectional epidemiological studies assessing the prevalence of GERD in the Russian population, studies on adult patients with GERD, and publications with detailed descriptive statistics that allow using the data in the meta-analysis.</p><p><strong>Results: </strong>The final analysis included 6 studies involving 34,192 subjects. The overall prevalence of GERD (prevalence of heartburn ± regurgitation once a week or more frequently) in the analyzed studies was 25.605% (95% confidence interval [CI] 17.913-34.147). The analysis used a random effect model, as there was significant heterogeneity between the results in both groups (I2=99.63%; <i>p<</i>0.0001). The overall mean age of GERD patients in the study population was 48.14 (95% CI 32.25-4.03) years. The prevalence of GERD in the male population was 23.653% (95% CI 13.351-35.832) and 25.457% (95% CI 17.094-34.849) in females.</p><p><strong>Conclusion: </strong>This meta-analysis demonstrated that GERD is a common esophageal disease in the Russian population, affecting approximately one in four country residents.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"751-756"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The prevalence of mutations underlying development of Helicobacter pylori resistance to antibiotics in Kazan].","authors":"E A Kupriyanova, S R Abdulkhakov, R К Ismagilova, D D Safina, A R Akhtereeva, R R Galimova, A G Safin, T V Grigoryeva, R А Abdulkhakov","doi":"10.26442/00403660.2024.08.202813","DOIUrl":"https://doi.org/10.26442/00403660.2024.08.202813","url":null,"abstract":"<p><strong>Background: </strong>One of the reasons for the decrease of <i>Helicobacter pylori</i> eradication effectiveness is its resistance to antibiotics.</p><p><strong>Aim: </strong>To examine the prevalence of <i>H. pylori</i> point mutations responsible for clarithromycin and levofloxacin resistance among the patients with upper gastrointestinal (GI) tract disorders in Kazan.</p><p><strong>Materials and methods: </strong>The study included 203 patients with symptoms of dyspepsia who underwent upper GI endoscopy at the University Hospital of Kazan Federal University (Kazan, Russia) in 2019-2021. DNA isolation from gastric antrum mucosal biopsies was performed using PureLink Genomic DNA Mini Kits (Thermo Fisher Scientific, USA). Polymerase chain reaction was performed using primers specific for the V-region of the <i>23S</i> gene and the A subunit DNA gyrase encoding <i>gyrA</i> gene region. The sequencing of obtained DNA fragments was performed on 3730 DNA Analyzer. The sequences were searched for point mutations responsible for <i>H. pylori</i> resistance to clarithromycin (A2143G, A2142G and A2142C193 mutations) and levofloxacin (mutations of the <i>gyrA</i> gene).</p><p><strong>Results: </strong><i>H. pylori</i> was detected in 47.78% of biopsy specimens using polymerase chain reaction. The proportion of <i>H. pylori</i> strains with mutations leading to clarithromycin resistance was 17.53%. Amino acid substitutions in the <i>gyrA </i>gene were found in 12.37% of samples. In case of two <i>H. pylori</i> strains (2.06%), dual resistance to clarithromycin and levofloxacin was found.</p><p><strong>Conclusion: </strong>So high incidence of mutations underlying the development of <i>H. pylori</i> resistance to clarithromycin and levofloxacin was observed among examined patients in Kazan.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"96 8","pages":"739-743"},"PeriodicalIF":0.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}